Authors
Department of Biochemistry, Zanjan University of Medical Sciences, Zanjan, Iran
Abstract
Keywords
Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/
1. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156(9):635-48. [PubMed: 22547473]. https://doi.org/10.7326/0003-4819-156-9-201205010-00006 PMid:22547473 PMCid:PMC3561467 |
||||
2. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol. 2005;23(29):7350-60. [PubMed: 16145060]. https://doi.org/10.1200/JCO.2005.03.3845 PMid:16145060 |
||||
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-74. [PubMed: 15328174]. https://doi.org/10.1158/1078-0432.CCR-04-0220 PMid:15328174 |
||||
4. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264-71. [PubMed: 16341146]. https://doi.org/10.1038/modpathol.3800528 PMid:16341146 |
||||
5. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 2010;4:35-41. [PubMed: 20697531]. https://doi.org/10.1177/117822341000400004 |
||||
6. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1-2):4-13. [PubMed: 19574486]. https://doi.org/10.3121/cmr.2009.825 PMid:19574486 PMCid:PMC2705275 |
||||
7. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717. [PubMed: 15894097]. https://doi.org/10.1016/S0140-6736(05)66544-0 PMid:15894097 |
||||
8. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39-51. [PubMed: 17611206]. https://doi.org/10.1056/NEJMra043186 PMid:17611206 |
||||
9. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26(15):2568-81. [PubMed: 18487574]. https://doi.org/10.1200/JCO.2007.13.1748 PMid:18487574 |
||||
10. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10(1):32-42. [PubMed: 19065135]. https://doi.org/10.1038/nrg2485 PMid:19065135 PMCid:PMC3215088 |
||||
11. Sarkar S, Longacre M, Tatur N, Heerboth S, Lapinska K. Histone deacetylases (HDACs): Function, mechanism, & inhibition. Encyclopedia Analytical Chem. 2014. | ||||
12. Zentner GE, Henikoff S. Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol. 2013;20(3):259-66. [PubMed: 23463310]. https://doi.org/10.1038/nsmb.2470 PMid:23463310 |
||||
13. Ahmad K, Henikoff S. Epigenetic consequences of nucleosome dynamics. Cell. 2002;111(3):281-4. [PubMed: 12419239]. https://doi.org/10.1016/S0092-8674(02)01081-4 PMid:12419239 |
||||
14. Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, et al. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot (Tokyo). 1990;43(12):1524-32. [PubMed: 2276972]. https://doi.org/10.7164/antibiotics.43.1524 PMid:2276972 |
||||
15. Hoshikawa Y, Kijima M, Yoshida M, Beppu T. Expression of differentiation-related markers in teratocarcinoma cells via histone hyperacetylation by trichostatin A. Agricultural Biological Chem. 1991;55(6):1491-5. https://doi.org/10.1271/bbb1961.55.1491 https://doi.org/10.1080/00021369.1991.10870799 |
||||
16. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res. 1994;214(1):189-97. [PubMed: 8082721]. https://doi.org/10.1006/excr.1994.1248 PMid:8082721 |
||||
17. Sugita K, Koizumi K, Yoshida H. Morphological reversion of sistransformed NIH3T3 cells by trichostatin A. Cancer Res. 1992;52(1):168- 72. [PubMed: 1727377]. | ||||
18. Yoshida M, Hoshikawa Y, Koseki K, Mori K, Beppu T. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J Antibiot (Tokyo). 1990;43(9):1101-6. [PubMed: 2211374]. https://doi.org/10.7164/antibiotics.43.1101 PMid:2211374 |
||||
19. Yoshida M, Nomura S, Beppu T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res. 1987;47(14):3688-91. [PubMed: 2439196]. | ||||
20. Yoshida M, Beppu T. Reversible arrest of proliferation of rat 3Y1 fibroblasts in both the G1 and G2 phases by trichostatin A. Experimental Cell Res. 1988;177(1):122-31. https://doi.org/10.1016/0014-4827(88)90030-4 PMid:3134246 |
||||
21. Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 1997;57(17):3697-707. [PubMed: 9288776]. | ||||
22. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26(37):5420-32. [PubMed: 17694083]. https://doi.org/10.1038/sj.onc.1210610 PMid:17694083 |
||||
23. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Lett. 2009;274(2):169-76. [PubMed: 18635312]. 4 Razavi Int J Med. 2017; 5(2):e55455. Rahimian A and Mellati A https://doi.org/10.1016/j.canlet.2008.06.005 PMid:18635312 |
||||
24. Vanhaecke T, Papeleu P, Elaut G, Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem. 2004;11(12):1629-43. [PubMed: 15180568]. https://doi.org/10.2174/0929867043365099 PMid:15180568 |
||||
25. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010;32(1-2):35-48. [PubMed: 21778573]. https://doi.org/10.3233/BD-2010-0307 PMid:21778573 PMCid:PMC3532890 |
||||
26. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs. 2007;16(5):659- 78. [PubMed: 17461739]. https://doi.org/10.1517/13543784.16.5.659 PMid:17461739 |
||||
27. Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 2007;7(4):583-98. [PubMed: 17428177]. https://doi.org/10.1586/14737140.7.4.583 PMid:17428177 |
||||
28. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003;100(18):10393-8. [PubMed: 12917485]. https://doi.org/10.1073/pnas.1732912100 PMid:12917485 PMCid:PMC193572 |
||||
29. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA. 2006;295(21):2492-502. [PubMed: 16757721]. https://doi.org/10.1001/jama.295.21.2492 PMid:16757721 |
||||
30. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64(3):830-5. [PubMed: 14871808]. https://doi.org/10.1158/0008-5472.CAN-03-2970 PMid:14871808 |
||||
31. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59(7):729-35. [PubMed: 16556664]. https://doi.org/10.1136/jcp.2005.033043 PMid:16556664 PMCid:PMC1860434 |
||||
32. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006;42(18):3149-56. [PubMed: 17055256]. https://doi.org/10.1016/j.ejca.2006.08.015 PMid:17055256 |
||||
33. Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007;9(1):R4. [PubMed: 17217540]. https://doi.org/10.1186/bcr1636 PMid:17217540 PMCid:PMC1851397 |